Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sep 9, 2024 | Press Releases

– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia – – Additional vocal biomarker data from ongoing open label extension...

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024 | Press Releases

CUPERTINO, Calif., Sept. 04, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

Aug 27, 2024 | Press Releases

CUPERTINO, Calif., Aug. 27, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024 | Press Releases

CUPERTINO, Calif., Aug. 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 14, 2024 | Press Releases

– Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 – – European patent granted covering...